News | January 06, 2012

Plans Made for Market Reintroduction of CardioGen-82

January 6, 2012 – Bracco Diagnostics said it plans to close out the recall process for its CardioGen-82 cardiac perfusion radiotracer with a list of actions to bring the product back to market.

The company instituted the product recall on July 29, 2011 after two cardiac patients who underwent positron emission tomography (PET) scans set off radiation detectors on the U.S. border. The increased level of radiation was due to a strontium (Sr) breakthrough from the radiotracer generator.

In a letter to customers released December 29, Bracco said during the past five months it performed the following actions:

CardioGen-82 Generator Voluntary Recall Process: All recalled generators were sent back to the manufacturer for functional and breakthrough testing. The generator testing demonstrated that each and every generator had Sr-82 and Sr-85 levels well within specification limits set forth in the prescribing information.

Clinical Assessment Program: Bracco continues to gather data in a clinical study (designated CGEN-105) at all participating institutions that have administered CardioGen-82 to patients from January 2011 through July 2011. To date, there have been no patients identified at these sites with higher than expected radiation levels.

Rb82 Generator Quality Review Program: Bracco initiated an on-site review of each facility’s daily quality control records, using the quality review process. This review was an opportunity to reinforce customer training and education and will be the basis for enhanced CardioGen-82 training quality control assessment and monitoring upon reintroduction of CardioGen-82 to the market.

Manufacturing Process Review: At the U.S. Food and Drug Administration’s (FDA) request, Bracco initiated the re-qualifying of all CardioGen components and revalidating of the manufacturing process.

Enhanced Labeling and User Training: Bracco continues to work with the FDA on enhancing the CardioGen-82 prescribing information and user training parameters to ensure proper field use. We will initiate a new quality control data repository and monitoring program upon the reintroduction of Cardiogen-82 to the market.

The company said it proposed to FDA a controlled and phased reintroduction of CardioGen-82 generators to user facilities, with data collection and evaluation of the actual field use of each generator beginning in the first quarter of 2012. Bracco said the FDA expressed support for this plan. The first step in this effort will be to implement customer requirements in advance of commercial generator availability. Bracco’s field nuclear medicine team will begin to contact each facility toward the end of January, discussing compliance training and site preparation expectations. Specific customer generator delivery schedules are not available at this time. However, customers can anticipate receiving additional information regarding generator availability by Feb. 1, 2012.

For more information: www.cardiogen.com

Related Content

Researchers Trace Parkinson's Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are major causes of...
PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017
In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new...
ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging | September 01, 2016
September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...
cardiac PET, myocardial perfusion, PET-CT, cardiac perfusion

A PET-CT cardiac perfusion exam from a Siemens Biograph scanner. The black and white areas of the image show the CT imaging of the anatomy. The colored portion shows the PET overlay on the myocardium and is color-coded to show tracer uptake values. This can show areas of the heart muscle where there are perfusion defects cause by infarcts or coronary artery blockages due to a heart attack and help determine the severity of the ischemia.

Feature | PET Imaging | June 03, 2016 | Dave Fornell
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enabl
blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging | September 23, 2015
September 23, 2015 — New research de
Overlay Init